These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35040012)

  • 1. Cocktails of KLK5 Protease Inhibitors and Anti-TNFα Therapeutics: an Effective Treatment for Netherton Syndrome.
    Zingkou E; Pampalakis G; Sotiropoulou G
    J Clin Immunol; 2022 Apr; 42(3):597-605. PubMed ID: 35040012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cathelicidin represents a new target for manipulation of skin inflammation in Netherton syndrome.
    Zingkou E; Pampalakis G; Sotiropoulou G
    Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165831. PubMed ID: 32442469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome.
    Furio L; Pampalakis G; Michael IP; Nagy A; Sotiropoulou G; Hovnanian A
    PLoS Genet; 2015 Sep; 11(9):e1005389. PubMed ID: 26390218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A proinflammatory role of KLK6 protease in Netherton syndrome.
    Zingkou E; Pampalakis G; Charla E; Nauroy P; Kiritsi D; Sotiropoulou G
    J Dermatol Sci; 2019 Jul; 95(1):28-35. PubMed ID: 31255470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KLK5 and KLK7 Ablation Fully Rescues Lethality of Netherton Syndrome-Like Phenotype.
    Kasparek P; Ileninova Z; Zbodakova O; Kanchev I; Benada O; Chalupsky K; Brattsand M; Beck IM; Sedlacek R
    PLoS Genet; 2017 Jan; 13(1):e1006566. PubMed ID: 28095415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
    Wang S; Olt S; Schoefmann N; Stuetz A; Winiski A; Wolff-Winiski B
    Exp Dermatol; 2014 Jul; 23(7):524-6. PubMed ID: 24848304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome.
    White GV; Edgar EV; Holmes DS; Lewell XQ; Liddle J; Polyakova O; Smith KJ; Thorpe JH; Walker AL; Wang Y; Young RJ; Hovnanian A
    Bioorg Med Chem Lett; 2019 Mar; 29(6):821-825. PubMed ID: 30691925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton syndrome.
    Walker AL; Bingham RP; Edgar EV; Ferrie A; Holmes DS; Liddle J; Polyakova O; Rella M; Smith KJ; Thorpe JH; Wang Y; White GV; Young RJ; Hovnanian A
    Bioorg Med Chem Lett; 2019 Jun; 29(12):1454-1458. PubMed ID: 31005442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome.
    Furio L; de Veer S; Jaillet M; Briot A; Robin A; Deraison C; Hovnanian A
    J Exp Med; 2014 Mar; 211(3):499-513. PubMed ID: 24534191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Potent and Selective Kallikrein-5 Inhibitor Delivers High Pharmacological Activity in Skin from Patients with Netherton Syndrome.
    Liddle J; Beneton V; Benson M; Bingham R; Bouillot A; Boullay AB; Brook E; Cryan J; Denis A; Edgar E; Ferrie A; Fouchet MH; Grillot D; Holmes DS; Howes A; Krysa G; Laroze A; Lennon M; McClure F; Moquette A; Nicodeme E; Santiago B; Santos L; Smith KJ; Thorpe JH; Thripp G; Trottet L; Walker AL; Ward SA; Wang Y; Wilson S; Pearce AC; Hovnanian A
    J Invest Dermatol; 2021 Sep; 141(9):2272-2279. PubMed ID: 33744298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Netherton syndrome: skin inflammation and allergy by loss of protease inhibition.
    Hovnanian A
    Cell Tissue Res; 2013 Feb; 351(2):289-300. PubMed ID: 23344365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrafamily and Interfamilial Phenotype Variation and Immature Immunity in Patients With Netherton Syndrome and Finnish SPINK5 Founder Mutation.
    Hannula-Jouppi K; Laasanen SL; Ilander M; Furio L; Tuomiranta M; Marttila R; Jeskanen L; Häyry V; Kanerva M; Kivirikko S; Tuomi ML; Heikkilä H; Mustjoki S; Hovnanian A; Ranki A
    JAMA Dermatol; 2016 Apr; 152(4):435-42. PubMed ID: 26865388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors.
    Walker AL; Denis A; Bingham RP; Bouillot A; Edgar EV; Ferrie A; Holmes DS; Laroze A; Liddle J; Fouchet MH; Moquette A; Nassau P; Pearce AC; Polyakova O; Smith KJ; Thomas P; Thorpe JH; Trottet L; Wang Y; Hovnanian A
    Bioorg Med Chem Lett; 2019 Oct; 29(20):126675. PubMed ID: 31521475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A viable mouse model for Netherton syndrome based on mosaic inactivation of the Spink5 gene.
    Kasparek P; Ileninova Z; Haneckova R; Kanchev I; Jenickova I; Sedlacek R
    Biol Chem; 2016 Dec; 397(12):1287-1292. PubMed ID: 27543783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual antibody inhibition of KLK5 and KLK7 for Netherton syndrome and atopic dermatitis.
    Chavarria-Smith J; Chiu CPC; Jackman JK; Yin J; Zhang J; Hackney JA; Lin WY; Tyagi T; Sun Y; Tao J; Dunlap D; Morton WD; Ghodge SV; Maun HR; Li H; Hernandez-Barry H; Loyet KM; Chen E; Liu J; Tam C; Yaspan BL; Cai H; Balazs M; Arron JR; Li J; Wittwer AJ; Pappu R; Austin CD; Lee WP; Lazarus RA; Sudhamsu J; Koerber JT; Yi T
    Sci Transl Med; 2022 Dec; 14(675):eabp9159. PubMed ID: 36516271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STAT3 maintains skin barrier integrity by modulating SPINK5 and KLK5 expression in keratinocytes.
    Kim J; Kim MG; Jeong SH; Kim HJ; Son SW
    Exp Dermatol; 2022 Feb; 31(2):223-232. PubMed ID: 34378233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model.
    Briot A; Lacroix M; Robin A; Steinhoff M; Deraison C; Hovnanian A
    J Invest Dermatol; 2010 Dec; 130(12):2736-42. PubMed ID: 20703245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a crystallographic surrogate for kallikrein 5 in the discovery of novel inhibitors for Netherton syndrome.
    Thorpe JH; Edgar EV; Smith KJ; Lewell XQ; Rella M; White GV; Polyakova O; Nassau P; Walker AL; Holmes DS; Pearce AC; Wang Y; Liddle J; Hovnanian A
    Acta Crystallogr F Struct Biol Commun; 2019 May; 75(Pt 5):385-391. PubMed ID: 31045568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel SPINK5 donor splice site variant in a child with Netherton syndrome.
    Mintoff D; Borg I; Vornweg J; Mercieca L; Merdzanic R; Numrich J; Aquilina S; Pace NP; Fischer J
    Mol Genet Genomic Med; 2021 Mar; 9(3):e1611. PubMed ID: 33534181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue Kallikrein Inhibitors Based on the Sunflower Trypsin Inhibitor Scaffold - A Potential Therapeutic Intervention for Skin Diseases.
    Chen W; Kinsler VA; Macmillan D; Di WL
    PLoS One; 2016; 11(11):e0166268. PubMed ID: 27824929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.